Brokerages Set Illumina, Inc. (NASDAQ:ILMN) Target Price at $170.90

Illumina, Inc. (NASDAQ:ILMNGet Free Report) has received an average recommendation of “Hold” from the nineteen research firms that are currently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation, nine have given a hold recommendation and eight have issued a buy recommendation on the company. The average 1-year target price among analysts that have covered the stock in the last year is $166.95.

ILMN has been the subject of a number of analyst reports. StockNews.com raised shares of Illumina from a “hold” rating to a “buy” rating in a research report on Wednesday. Piper Sandler decreased their price objective on shares of Illumina from $200.00 to $190.00 and set an “overweight” rating for the company in a research note on Monday, November 13th. Barclays boosted their price objective on shares of Illumina from $50.00 to $80.00 and gave the stock an “underweight” rating in a research note on Thursday, January 25th. Scotiabank upgraded shares of Illumina from a “sector perform” rating to a “sector outperform” rating and set a $185.00 price objective for the company in a research note on Monday, December 18th. Finally, HSBC downgraded shares of Illumina from a “buy” rating to a “hold” rating in a research note on Tuesday, January 16th.

Check Out Our Latest Stock Report on ILMN

Illumina Trading Down 1.3 %

NASDAQ ILMN opened at $142.94 on Monday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.28 and a current ratio of 1.69. The firm has a market cap of $22.70 billion, a PE ratio of -20.08, a P/E/G ratio of 25.62 and a beta of 1.22. Illumina has a one year low of $89.00 and a one year high of $238.55. The firm’s fifty day moving average is $133.85 and its two-hundred day moving average is $138.64.

Illumina (NASDAQ:ILMNGet Free Report) last released its quarterly earnings data on Thursday, November 9th. The life sciences company reported $0.33 EPS for the quarter, topping analysts’ consensus estimates of $0.13 by $0.20. Illumina had a negative net margin of 25.20% and a positive return on equity of 2.13%. The firm had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.13 billion. During the same quarter in the previous year, the firm earned $0.34 earnings per share. The firm’s revenue was up .4% on a year-over-year basis. Analysts expect that Illumina will post 0.72 earnings per share for the current year.

Hedge Funds Weigh In On Illumina

Institutional investors have recently modified their holdings of the company. J.P. Morgan Private Wealth Advisors LLC acquired a new stake in Illumina during the third quarter worth $29,558,000. Van ECK Associates Corp raised its holdings in shares of Illumina by 1.7% in the second quarter. Van ECK Associates Corp now owns 112,444 shares of the life sciences company’s stock valued at $21,082,000 after buying an additional 1,861 shares during the last quarter. Achmea Investment Management B.V. raised its holdings in shares of Illumina by 57.1% in the second quarter. Achmea Investment Management B.V. now owns 421 shares of the life sciences company’s stock valued at $79,000 after buying an additional 153 shares during the last quarter. Harvest Fund Management Co. Ltd raised its holdings in shares of Illumina by 60.6% in the third quarter. Harvest Fund Management Co. Ltd now owns 1,246 shares of the life sciences company’s stock valued at $171,000 after buying an additional 470 shares during the last quarter. Finally, Perceptive Advisors LLC bought a new position in shares of Illumina in the second quarter valued at about $27,186,000. Institutional investors own 92.17% of the company’s stock.

About Illumina

(Get Free Report

Illumina, Inc develops, manufactures, and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; and whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

Read More

Analyst Recommendations for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.